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Abstract
The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical 
conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, 
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immune dysregulation and potential complications. The inci-
dence of Alzheimer’s disease (AD) is much higher in DS 
than in the general population, possibly increasing further 
the risk of COVID-19 infection and its complications. Here 
we provide a biological overview with regard to specific 
susceptibility of individuals with DS to SARS-CoV-2 infec-
tion as well as data from a recent survey on the prevalence 
of COVID-19 among them. We see an urgent need to protect 
people with DS, especially those with AD, from COVID-19 
and future pandemics and focus on developing protective 
measures, which also include interventions by health sys-
tems worldwide for reducing the negative social effects of 
long-term isolation and increased periods of hospitalization.
Keywords COVID-19 · Down syndrome · Immune 
dysregulation · SARS-CoV-2 · Vaccine
Overview
The current COVID-19 pandemic, caused by the SARS-
CoV-2 virus, is of widespread concern for the elderly people 
and populations at risk due to co-existing medical condi-
tions, including cardiovascular diseases, obesity, and diabe-
tes. Individuals with Down syndrome (DS) appear to have a 
significantly higher risk of developing severe symptoms of 
infectious diseases, including those related to COVID-19, 
because of their complex trisomy and consequent numer-
ous immune impairments, which render them suscepti-
ble to infections. Chromosome 21 (Chr21), triplicated in 
individuals with DS, includes genes directly involved in 
SARS-CoV-2 entry into cells, potentially augmenting 
COVID-19-specific susceptibility (Fig. 1). Clinically, these 
immune dysregulations often result in ineffective vaccina-
tion against infectious diseases. COVID-19-related risks, 
such as anatomical airway features, which enhance airway-
related infections, congenital heart disease, hypertension, 
obesity, and diabetes, are prevalent in individuals with DS. 
The immune anomalies of individuals with DS suggest that 
any COVID-19-directed therapy developed for the general 
population requires careful testing prior to implementation 
in the clinic. Not least important is the additional aspect of 
social isolation experienced by numerous at-risk individu-
als in general and individuals with DS in particular (Fig. 1). 
Individuals with DS are often dependent on regular sched-
ules, which, upon interruption, can impair their mental 
health. Measures to avert the implications of social isolation 
in this vulnerable population, therefore, need to be taken into 
consideration. This complex picture calls for an immediate 
reorganization towards better preparedness for future pan-
demics in vulnerable populations, including DS.
Down Syndrome–Prevalence and Lifespan
DS is the most common genetic disorder of cognition; essen-
tially, all those with DS demonstrate intellectual disability 
(ID), though of variable degree. Chr21 contains approxi-
mately 233 protein-coding genes, some of which, like amy-
loid precursor protein (APP) and dual-specificity tyrosine 
phosphorylation-regulated kinase 1A (DYRK1A), have been 
linked to an Alzheimer’s disease (AD)-like phenotype. DS 
occurs in all populations with an average worldwide preva-
lence of 3.3–6.7 per 10,000 individuals that varies between 
countries (Antonarakis et al. 2020) (Fig. 2, Supplementary 
Data 1).
In the 1940s, the average life expectancy for people 
with DS was 12 years (Penrose, 1949). With advances and 
increased access to medical care and early surgical repair 
of congenital heart malformations, individuals with DS 
Fig. 1  Susceptibility factors 
to COVID-19 in Down’s syn-
drome. Top bar; Cellular-level 
susceptibility factors. Middle 
bar; System-level susceptibility 
factors. Lower bar; patient-level 
susceptibility factors. All these 
factors culminate in increased 
susceptibility of individuals 
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currently have an average life expectancy of 60 years (Bit-
tles & Glasson, 2004). The risk for mortality in younger 
people with DS is increased mainly because of leukemia 
and respiratory infections. As a result of increased life 
expectancy, a greater number of individuals with DS now 
exhibit age-related diseases, such as AD—the principal 
cause of death in the elderly with DS, which may increase 
their risk for emerging pathogens such as SARS-CoV-2. A 
significant vulnerability to infections impacts individuals 
with DS after the age of 50 years, especially those with 
certain comorbidities, like seizures and age-related onset 
of dementia (Guffroy et al. 2019).
Comorbidities in DS as Risk Factors 
for Emerging Infectious Diseases
Obesity, increasing age, male sex, hypertension, and dia-
betes are risk factors associated with increased mortality 
from COVID-19 in the general population (Brenner et al. 
2020; George et al. 2020; Palaiodimos et al. 2020) and are 
also present in DS, combining to increase susceptibility to 
infectious diseases including SARS-CoV-2. Certain ana-
tomical features contribute a short stature, a flat and wide 
face with a flat nasal ridge, slanted eyes, a short neck, and 
a protruding tongue due to a small orofacial cavity and 
a relatively large tongue (Kanamori et al. 2000). These 
features impact the airway tract and may contribute to 
the increase in obstructive sleep apnea and upper airway 
obstruction found in 50% of those with DS (Horne et al. 
2019; Marcus et al. 1991). Intervention with respiratory 
support may therefore prevent COVID-19-related conse-
quences of sleep-disordered breathing (Trucco et al. 2018).
Pulmonary hypertension is diagnosed in 13% of those 
with DS (Berger et al. 2012). This condition and develop-
mental lung anomalies (Cooney & Thurlbeck, 1982) may 
combine to increase the risk of COVID-19 in people with 
DS (Bush et al. 2020), due to reduced oxygen capacity 
and supply.
Obesity, due to lower thyroid and a lower metabolic 
rate, and ID co-occur significantly more often than in the 
general population. Obesity is associated with decreased 
expiratory reserve volume and functional capacity. 
Abdominal obesity compromises pulmonary function in 
immobilized patients by decreased diaphragmatic excur-
sion and reducing ventilation efficacy. Obesity is also asso-
ciated with higher levels of inflammatory cytokines, con-
tributing to increased morbidity associated with obesity 
in COVID-19 infections (Dietz & Santos-Burgoa, 2020). 
Obesity is also associated with obstructive sleep apnea, 
another very common condition in individuals with DS, 
which, if left untreated, can lead to hypertension, heart 
failure and sudden death.
Additionally, the frequency of congenital heart disease 
varies from 40 to 54% in DS (Freeman et al. 1998). The 
cardiac defects are usually treated by pediatric cardiac 
surgery at an early age (Jensen et al. 2014). As for those 
with congenital heart diseases, individuals with DS are 
known to have a higher risk for complications with viral 
illnesses, including respiratory syncytial virus and influ-
enza (Alsaied et al. 2020; Weijerman et al. 2010).
Prevalence of Infectious Diseases 
and Associated Hospitalizations in Down 
Syndrome
Bacteria such as Streptococcus pneumonia are the major 
cause of pneumonia in individuals with DS (Verstegen 
et al. 2014), while viruses such as influenza virus, res-
piratory syncytial virus (RSV), and parainfluenza virus 
account for most respiratory infections in DS (Chan et al. 
2017). RSV, a double-stranded RNA (dsRNA) virus, is 
the primary cause of severe lower respiratory tract infec-
tions (LRI) in young children (< 5 years) (Beckhaus & 
Fig. 2  Worldwide prevalence 
of DS. Data collected from the 
Global Health Data Exchange 
(GHDx; http://ghdx.healt hdata 
.org/) were used to calculate 
the total worldwide prevalence 




Castro-Rodriguez, 2018; Perez-Padilla et al. 2010). Chil-
dren with DS are at risk for RSV infections (Beckhaus 
& Castro-Rodriguez, 2018; Mitra et al. 2018), especially 
those who have chronic lung disease or congenital heart 
disease.
Following the outbreak of the H1NI 2009 pandemic 
in Mexico, a study found a 16-fold increase in hospitali-
zation, an eightfold increase in endotracheal intubation, 
and a more than 300-fold increase in death in individuals 
with DS in Mexico (Perez-Padilla et al. 2010). Moreover, 
DS patients were significantly younger as compared with 
affected individuals of the general population. Thus, com-
pared with the general population, DS is associated with 
increased susceptibility to bacterial and viral infections at 
a younger age, resulting in worse outcomes, higher hospi-
talization rates, longer hospital stays, and higher mortality 
rates.
These findings point to respiratory infections as a sig-
nificant source of increased morbidity and mortality in 
children with DS and suggest that this will apply to infec-
tion with COVID-19 in both children and adults with DS.
A recent study, reported an increased severity of 
COVID-19 in hospitalized patients with DS (Malle et al. 
2020). This dual-center study of 7246 patients hospital-
ized with COVID-19 in the city of New York, assessed 
the hospitalization rates, clinical characteristics, and out-
comes. The researchers identified 12 patients with DS, and 
reported that their average age was ten years younger than 
patients without DS. The incident of severe disease was 
higher in those patients, specifically an increased incident 
of sepsis and mechanical ventilation. Moreover, a descrip-
tion of the clinical course in four COVID-19 patients with 
DS in Belgium, revealed severe illness in three of the four 
cases with fatal outcome in one patient (De Cauwer & 
Spaepen, 2020).
Immune Dysregulation and Aging in Down 
Syndrome vis‑a‑vis Vaccines
Individuals with DS have reduced lymphocyte numbers 
(Huggard et al. 2018; MacLean et al. 2018), thought to be 
a result of increased thymic dysfunction and apoptosis of 
immune cells (Schoch et al. 2017; Zampieri et al. 2014). 
The thymus is smaller in DS infants than in non-DS infants 
and exhibits structural abnormalities (Carsetti et al. 2015; 
Eijsvoogel et al. 2017), arguing that immune dysregula-
tion and immunodeficiency are integral to the syndrome 
(Carsetti et al. 2015; Huggard et al. 2018). The selective 
cell-mediated immunodeficiency and impaired antibody 
response to pathogens in DS can be associated with the 
mortality associated with pneumonia and other respiratory 
diseases in children with DS (Chaushu et al. 2002; Costa-
Carvalho et al. 2006).
Type I interferons (IFNs) are a group of proteins that 
help regulate the activity of the immune system. DS is 
characterized by constitutive IFN-I signaling; this may be 
a major cause of suboptimal vaccine responses in people 
with DS. This raises the question as to whether SARS-
CoV-2 vaccines shown effective in otherwise healthy 
young hosts will prove effective in people with DS. It is 
premature to conclude that the DS population will fail to 
respond to SARS-CoV-2 vaccines that are effective in the 
general population. However, this should be proactively 
explored through studies in which strategies that block 
high levels of IFN-I signaling or upregulation of IFN 
receptors are tested. Alternatively, vaccine responses can 
be improved using immune modulators, such as interleukin 
(IL)-21, or activating downstream signaling effectors of 
IL21, such as the STAT3 pathway, known to contribute 
to long-lived antibody-secreting cells in humans (Avery 
et al. 2010).
Initial response to vaccines is generally adequate in 
individuals with DS but with lower mean titers and a 
need for more frequent booster immunizations compared 
to individuals without DS (Eijsvoogel et al. 2017). Many 
of these immunological alterations are age related and 
can be envisioned as within the spectrum of early senes-
cence of the immune system, which is typically seen in 
the elderly (da Rosa Utiyama et al. 2008; Trotta et al. 
2011). Indeed, premature aging in multiple body tissues 
is evident in DS (Zigman, 2013). Specifically, molecu-
lar aging in DS is more pronounced in individuals with 
DS that experience dementia compared with individuals 
with DS without apparent dementia. For example, telom-
eres are chromosome ends consisting of highly conserved 
TTA GGG repeats whose number progressively reduced 
with aging (Shay, 2018). Immune T cell lymphocyte cul-
tures from people with DS and AD-related dementia have 
shorter telomeres than T-lymphocytes from age- and sex-
matched people with DS with no dementia (Jenkins et al. 
2008, 2010), a phenomenon that precedes the late stages 
of dementia in DS (Jenkins et al. 2012).
Specific Predisposition to Severe COVID‑19 
in DS
Cell attachment and entry is a critical step in the pro-
cess of viral infection. Of particular relevance to DS is 
the TMPRSS2 gene, located within Chr21 (De Cauwer, 
2020; Paoloni-Giacobino et al. 1997). TMPRSS2 is a pro-
tease involved in SARS-CoV-2 entry into cells via prim-
ing of S protein; TMPRSS2 overexpression might result 
in a higher number of infected cells that could potentially 
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augment COVID-19 susceptibility in DS. It was recently 
reported that a TMPRSS2 inhibitor, approved for clinical 
use, blocked entry of SARS-2-S to lung cells (Hoffmann 
et al. 2020), therefore might constitute a treatment option 
for patients with DS. Furthermore, viruses, including SARS-
CoV, enter cells by hijacking mechanisms, like phagocy-
tosis via the endocytosis pathways (Cataldo et al. 2008; 
Inoue et al. 2007). Dysregulation of endocytosis in DS is 
likely a function of an increased dose of several endosomal 
pathway-related genes that map to Chr21, including APP, 
SYNJ1 (Synaptojanin-1), ITSN1 (Intersectin-1), and pos-
sibly RCAN1 (Regulator of calcineurin 1) (Botte & Potier, 
2020; Patel et al. 2015). Studies focused on neurons showed 
that APP, known to mediate dementia in DS, is involved in 
altered trafficking of viral material and modified pH-depend-
ent fusion of viruses with an endosomal membrane in DS 
(Botte & Potier, 2020; Jiang et al. 2016; Kim et al. 2016).
Adults with DS exhibit elevated levels of the proinflam-
matory cytokines IL-6 and TNF-α (Altable & de la Serna, 
2021), along with hyperactivity of interferon signaling, 
possibly due to IFNAR1, IFNAR2, IFNGR2 and IL10RB 
overexpression (Espinosa, 2020). Hypothetically, these 
dysregulations support the notion that DS individuals are 
at increased risk of exacerbated cytokine storm following 
COVID-19 infection. However, this hypothesis is not yet 
backed with data from humans.
Children with ID have a higher prevalence of specific 
comorbidities associated with poorer COVID-19 outcomes 
(Turk et al. 2020). No specific data on COVID-19 prevalence 
in pediatric patients with DS is currently available. Never-
theless, several case studies were recently described in such 
patients (Alsahabi et al. 2021; Kantar et al. 2020; Newman 
et al. 2021; Pontes et al. 2020). Out of the total of 10 cases 
presented in these publications, 3 (33%) were admitted to the 
ICU, 2 (20%) required intubation and none had died.
Given this and related factors discussed above, individu-
als with DS may be at higher risk of SARS-CoV-2 infection 
and poorer clinical outcomes.
Vaccination Strategies
The majority of vaccination strategies in the race to con-
trol the COVID-19 aim to induce neutralizing antibodies to 
the SARS-CoV-2 by targeting its Spike (S) antigen and its 
binding to angiotensin converting enzyme 2 (ACE2), which 
serves as the primary mechanisms by which the virus enters 
cells. Elderly individuals, people with type-2-diabetes, 
morbidly obese individuals, and individuals with DS are in 
general poor responders to vaccines (Corretger, 2014). Two 
concerns attend considerations of vaccine development in 
the context of DS. COVID-19 vaccines may be challenged in 
their ability to elicit long-term protection in DS. Due to sub-
optimal primary and memory immune responses, vaccines 
often prove inefficient protection in DS (Costa-Carvalho 
et al. 2006). Moreover, even if a vaccine generates an adap-
tive immune response, it may induce persistent, even life-
long, overactivation of innate immune cells in DS. Indeed, 
antibodies against SARS-CoV-2 antigens could exacer-
bate an already heightened immune response. Antibody-
dependent enhancement of infection can also occur due to 
innate immune cell dysregulation, impaired destruction of 
phagocytosed immune complexes, or/and altered expression 
of Fc receptors, which recognize Fc fragment of antibod-
ies and mediate downstream signaling. Achieving optimal 
responses in DS should be seen as an important research 
topic. One potential strategy would include the use of a con-
jugated pneumococcal vaccine, shown to induce antibodies 
responses in individuals with DS that are equally effective 
as in non-DS individuals (Kusters et al. 2013).
Fig. 3  Spearman correla-
tion between COVID-19 and 
different diseases. Spearman 
correlation between COVID-
19-related deaths (normalize to 
1 million) and different patholo-
gies. A positive significant 
Spearman correlation was found 
between COVID-19 and DS, 
AD, cardiovascular diseases, 
thyroid cancer and leukemia
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Data on the Susceptibility of Individuals 
with DS to COVID‑19
For an initial assessment, data on the prevalence of DS per 
country, as well as death rates from different diseases in 
61 countries, were collected from the Global Health Data 
Exchange (GHDx) (http://ghdx.healt hdata .org/, Sep 2020). 
COVID-19-related data were obtained from the WORL-
DOMETER database (https ://www.world omete rs.info/, 
Sep 2020). A significant correlation was observed between 
COVID-19-related deaths (normalized to 1 million in every 
country) and the prevalence of DS per country (r = 0.39, 
p-value = 0.0022, Spearman Correlation Coefficient (SCC)). 
By means of SCC, we observed that SARS-CoV-2 infec-
tions were positively correlated with DS-related comor-
bidities such as AD and dementia (SCC = 0.73, p < 0.0001), 
cardiovascular diseases (SCC = 0.66, p < 0.0001), leukemia 
(SCC = 0.72, p < 0.0001), and thyroid cancer (SCC = 0.71, 
p < 0.001) (Fig. 3), suggesting that DS-related comorbidities 
are a risk factor for COVID-19.
‘Leumit’ Health Care Services (LHS) is a health mainte-
nance organization that covers 712,773 residents in Israel, 
including 570 residents with DS (0.08%). The LHS study 
included 115,050 subjects, (from February 1st until Decem-
ber 31st, 2020) aged 1 month to 106 years old, who were 
tested for SARS-CoV-2. Among them, 10,469 (9.1%) had 
at least one positive result, and 104,581 (90.9%) were nega-
tive for SARS-CoV-2 (Table 1). COVID-19 positive indi-
viduals were of lower socioeconomic status (SES) and were 
mostly males (Table 1). The prevalence of DS in the general 
population in Israel is 0.11% (GHDx, Sep 2020). The preva-
lence of DS individuals that were tested positive to COVID-
19 in the LHS database is higher than their proportion in the 
general population (0.19% of all COVID-19 positive cases). 
We then calculated the crude odds ratio (OR) for the general 
population of LHS enrollees and individuals with DS that 
were positive for COVID-19 and we found OR = 2.33, 95% 
CI 1.08–3.45, (p = 0.023). However, we did not find signifi-
cance when we compared COVID-19 positive cases in the 
Table 1  Demographic 
characteristics of subjects 
with DS and controls in the 
LHS records of SARS-CoV-2 







Mean age, (years, CI) 31.40 (30.98–31.82) 32.28 (34.12–34.43) 0.001
Social-economic status (SES) N (%)
 Low-medium 8,165 (78.0%) 66,618 (63.7%) 0.001
 High-medium 1,764 (16.85%) 30,082 (28.76%)
 Missing data 539 (5.15%) 7,881 (7.54%)
Gender N (%)
 Male 5,611 (53.6%) 50,617 (48.4%) 0.001
 Female 4,858 (46.4%) 53,964 (51.6%)
Down Syndrome 20 (0.19%) 115 (0.11%) 0.062
Obesity 1,818 (17.37%) 17,747 (16.97%) 0.028
Depression/Anxiety 342 (3.27%) 4,361 (4.17%) 0.001
Dementia 150 (1.44%) 2,802 (2.68%) 0.451
Schizophrenia 105 (1.01%) 1,307 (1.25%) 0.045
Chronic Lung Disease 768 (7.34%) 11,022 (10.54%) 0.001
Diabetes Mellitus 768 (7.34%) 9,129 (8.73%) 0.001
Hypertension 1,149 (10.98%) 16,283 (15.57%) 0.297
Ischemic Heart Disease 473 (4.52%) 7,948 (7.60%) 0.001
Heart Failure 99 (0.95%) 2,081 (1.99%) 0.124
Table 2  Multivariate logistic regression for being COVID-19 positive 
for all patients tested for SARS-CoV-2
*adjusted for sex, age, SES, and comorbidity
Variable Adjusted Odds Ratios (95% 
confidence intervals)*
P-value
Down Syndrome 1.64 (0.98–2.97) 0.052
Male Gender 1.20 (1.14–1.26) 0.001
Low-medium- SES* 2.01 (1.88–2.15) 0.001
Obesity 1.17 (1.09–1.25) 0.001
 Depression 0.98 (0.86–1.13) 0.861
 Schizophrenia 0.87 (0.69–1.10) 0.268
 Dementia 0.87 (0.70–1.09) 0.238
Chronic Lung Disease 0.72 (0.66–0.79) 0.001
Diabetes Mellitus 1.11 (1.01–1.24) 0.031
Hypertension 0.85 (0.77–0.94) 0.002
Ischemic Heart Disease 0.72 (0.63–0.99) 0.001
Heart Failure 0.77 (0.60–0.99) 0.044
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general population with COVID-19 positive cases in indi-
viduals with DS, OR = 1.53, 95% CI 0.91–2.58, (p = 0.12) 
(Table 1). Surprisingly, chronic medical conditions such as 
dementia, cardiovascular disease and chronic lung disease 
that are considered to be risk factors for COVID-19 in previ-
ous studies, were not found as increasing the rate of infection 
in the LHS cohort (Table 1). It is possible that this is due 
to the severe social distancing imposed on all the popula-
tion, and due to reduced social interaction by patients with 
chronic medical conditions.
The multiple logistic regression model for all patients 
tested for SARS-CoV-2 was applied to adjust for possible 
confounders. An association between DS and the likelihood 
of being tested positive for SARS-CoV-2 was significant 
(adjusted OR 1.64 (95% CI 0.98–2.97; p = 0.05) (Table 2). 
COVID-19 positive patients were mostly males (adjusted 
OR 1.20 (95% CI 1.14–1.26), with a lower-medium SES 
OR 2.01 (95% CI 1.88–2.15), and obese OR 1.17 (95% 
1.09–1.25) (Table 2).
Individuals with DS who were positive for COVID-19 were 
younger compared with non-DS individuals who were positive 
for COVID-19 (18.48 (13.40–23.56) vs. 31.43 (31.00–31.85) 
years, p-value < 0.001). SES or gender were not a contribut-
ing factor to this difference (Table 3). Moreover, chronic lung 
disease was significantly more prevalent in SARS-CoV-2-pos-
itive individuals with DS (Table 3). These data suggest that 
individuals with DS have an increased risk for SARS-CoV-2 
infection, particularly those with higher rates of chronic lung 
disease (p-value < 0.001, Table 3, and supplementary meth-
ods). Indeed, a survey that recently assessed the suceptability 
to COVID-19 in DS found that the mean age of COVID-19 
patients with DS was lower than the general population. In 
addition, mortality rates were increased in individuals with 
DS aged 40 and above (Hüls et al. 2021).
Quality of Life in Individuals with DS 
during Social Distancing
Mention has been made about of the behavioral charac-
teristics of people with DS that may feature in their sus-
ceptibility to infection and their physiological responses 
once infected. People with DS enjoy and are likely to have 
frequent contact with family members, caregivers, support 
staff, and people in the community, possibly increasing 
their risk of contact with infected individuals. Further-
more, they may have difficulty in understanding the impor-
tance of social distancing and wearing masks as a means 
of protecting against virus infection. Another important 
consideration is the potential impact of the pandemic on 
the behaviors and stress experienced by those with DS. 
Individuals with DS use routines and repetition to help 

























































































































































































































































































































their mental health. These behaviors include performing 
tasks at the same time and in the same way. Interrupting 
with these routines could, therefore, significantly affect 
their sense of wellbeing. Older adults with DS tend to be 
physically and cognitively frailer than those in the general 
population. As a consequence, they often live in sheltered 
community residences, assisted group living situations, 
and nursing homes. Social distancing recommendations 
in the context of the pandemic raise the possibility that 
people with DS experience increased stress, anxiety and 
depression and loss of social connectivity, which com-
bine to compromise mental health concerns and induce 
undesirable changes in behavior. Furthermore, receiving 
a vaccine, as well as any other invasive medical proce-
dure, may contribute to the stress burden experienced by 
individuals with DS during the pandemic. In this respect, 
those with DS may be representative of those in the gen-
eral population who live in similar settings, especially 
those with dementia. As one approach to safely mitigat-
ing the deleterious effects of social distancing, the use of 
digital technology may provide a means by which to allow 
people with DS and those with memory loss and dementia 
to reengage with caregivers, family, and friends. Activities 
in a virtual space also enable availability and accessibility 
to services and information and improve the range of pos-
sibilities for communicating in a risk-free environment. 
These methods may prove useful for the elderly in general 
and people with DS and other sources of ID for bridging 
physical, geographical, and financial barriers (Caton & 
Chapman, 2016).
Concluding Remarks
Here we have provided an overview of the contributing sus-
ceptibility factors to COVID-19 infection in DS, with a spe-
cial focus on adults with DS. The picture that emerges from 
the immunological and clinical aspects of individuals with 
DS points to the alarming conclusion that these individuals 
are at increased risk for contracting specific types of infec-
tious diseases and infection-related deaths.
There is a critical knowledge gap with respect to the 
underlying immune dysregulation and the specific vulner-
abilities of individuals with DS to COVID-19. For exam-
ple, the influence of human leukocyte antigen (HLA) gene 
polymorphisms on SARS susceptibility, pathogenesis, 
and outcome has been investigated in a number of studies. 
Some HLA alleles have been significantly associated with 
susceptibility to SARS and/or disease severity in various 
populations.
In addition, HLA alleles can be computationally predicted 
for their binding capability to SARS‐CoV‐2 peptides, pre-
dicting host susceptibility for COVID-19 disease (Ovsyan-
nikova et al. 2020). Despite this, little is known about HLA 
polymorphism in the DS population. Therefore, sequencing 
HLA types in DS patients worldwide is needed to enable 
a more rapid correlation between infection rate and HLA 
typing in affected DS patients. This will allow mapping of 
protective as well as harmful HLA types in DS.
Preparedness for Future Pandemics
Future pandemics could pose a similar or even higher risk 
for this susceptible population. One of the clear conclusions 
is that we need to increase the preparedness to future pan-
demics in individuals with DS in light of their increased and 
specific susceptibility. Better preparedness with respect to 
lifestyle, medical practice and basic research can be achieved 
mainly by forming an international network of experts in 
various fields, including immunology, epidemiology, neu-
rology, and sociology. With this in mind, the Trisomy 21 
Research society has established a COVID-19 task force and 
a stakeholders group with representatives from all major DS 
organizations in Europe, the U.S., and further afield.
This calls for a need to formulate steps to increase pre-
paredness for such a pandemic by family members and clini-
cians. These steps should include:
1. Establishing a DS-specific worldwide database on 
pandemic-related symptoms and hospitalizations and 
response to treatment. Such a database will enable a 
close to a real-time understanding of the specific suscep-
tibility of individuals with DS to pandemics and could 
be used or linked with existing surveillance efforts.
2. Establishing virtual social network(s) that can be acti-
vated during pandemics to support caregivers and the 
social welfare of individuals with DS. Such networks 
can partially help mitigate the adverse effects of social 
isolation during pandemics.
3. Promoting healthy lifestyle changes, for example lower-
ing obesity.
4. Reducing general risk factors in individuals with DS. For 
example in the COVID-19 relevant medical practices 
include (i) improving lung health by reducing chronic/
regular respiratory infections by offering influenza and 
pneumococcus vaccines, (ii) screening for and treating 
sleep apnea as well as other risk factors such as aspira-
tion, (iii) responding early to signs of lung infection to 
help reduce the risk of COVID-19, and (iv) increasing 
surveillance and protection of high-risk older individu-
als, particularly those who also show signs of AD.
5. Confirming the increased risk for infection and presenta-
tion in individuals with DS when affected by COVID-19 
and future pandemics.
6. Studying the clinical outcomes following COVID-19 
and response to treatment in individuals with DS. The 
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Long-term sequelae following recovery from acute 
COVID-19 need to be considered to understand the need 
for long-term management in the context of the impaired 
immune response in individuals with DS.
7. Establishing prior to widespread immunization whether 
the response to vaccines against SARS-CoV-2 in indi-
viduals with DS is similar to the response the general 
population.
Implementing these steps will help to support an effective 
response to future pandemics that is supportive not only of 
individuals with DS but also of family members, caregivers 
and clinicians, thus providing a much-needed safety net for 
this unique and vulnerable population.
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were used for identification of comorbidities.
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chronic bronchitis (490–496).
Diabetes–ICD-9 codes 250.00- 250.93.
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Obesity was considered as a measurement of BMI > 30 m2/kg.
Depression–ICD‐9 codes: 296.20‐296.25, 296.30‐296.35, 300.4, 311, 
309.0,309.28.
Dementia–ICD‐9 codes: 290.0 -290.4, 331.00, 331.1.
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Socioeconomic status (SES) data was taken from the Israeli Central 
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